A phase I/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer.

Trial Profile

A phase I/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Mar 2012

At a glance

  • Drugs BCG (Primary) ; Mitomycin (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Mar 2012 Planned end date changed from 11 Feb 2013 to 1 Sep 2013 as reported by as reported by European Clinical Trials Database.
    • 03 Mar 2012 Actual initiation date changed from 11 Feb 2011 to 4 Mar 2011 as reported by as reported by European Clinical Trials Database.
    • 23 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top